Legend Biotech Announces Positive CHMP Opinion for CARVYKTI

23.02.2024 - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expansion of the CARVYKTI ...

Related Keywords

Spain , Japan , New Jersey , United States , China , American , , Cancer Center Clinica Universidad De Navarra , Johnson , Cancer Center Clinica Universidad De Navarra Spain , European Commission , Twitter , Legend Biotech Corporation Stock , Japan Ministry Of Health , Exchange Commission On , American Cancer Society , Janssen Biotech Inc , Drug Administration , American Society Of Clinical Oncology , Linkedin , Medicinal Devices Agency , San Miguel , Senior Consultant , Release Syndrome , Effector Cell Associated Neurotoxicity Syndrome , Macrophage Activation Syndrome , Risk Evaluation , Mitigation Strategy , Mediated Myelitis , Nerve Palsies , Janssen Biotech , Prescribing Information , Boxed Warning , Legend Biotech , Breakthrough Therapy Designation , Orphan Drug Designation , European Medicines , Orphan Medicinal Products , Private Securities Litigation Reform Act , Annual Report , Exchange Commission , Professor Jes , Study Comparing , Versus Pomalidomide , Participants With Relapsed , Lenalidomide Refractory Multiple Myeloma , Accessed Nov , Accessed March , Statistics About Multiple Myeloma , Accessed February , Legend Biotech Corporation Chart , Egend Biotech Corporation Kurs , Egend Biotech Corporation Aktie ,